|
市場調查報告書
Seattle Genetics, Inc.:企業概要
Seattle Genetics, Inc.: PharmaVitae Report
| 出版商 |
Datamonitor |
| 出版日期 |
2011年11月 |
商品編碼 |
229441 |
| 內容資訊 |
英文 Pages: 34 |
| 價格 |
|
|
Seattle Genetics, Inc.:企業概要 是由出版商Datamonitor在2011年11月所出版的。
這份英文市場調查報告書包含Pages: 34 價格從美金5700起跳。
本報告提供醫藥品產業上的Seattle Genetics, Inc.相關調查分析，提供其實際成果及未來預測，以及產品分析與預測，開發平台評估，企業策略的評估，6年的財務實際成果等等，為您概述為以下內容。
執行摘要
關於本報告
- PharmaVitae:企業資料資料庫
- 本報告的章組成
- 資料的資訊來源
銷售額·產品分析
- 銷售額概要
- 產品分析
- Adcetris(brentuximab vedotin)
- 何杰金氏淋巴瘤的背景
- 異生性大細胞淋巴瘤的背景
- Adcetris的臨床實驗
- 何杰金氏淋巴瘤的樞紐試驗
- 異生性大細胞淋巴瘤的樞紐試驗
- 進展中·計劃中的臨床實驗
- 臨床及商業性魅力
- 預測的主要前提條件
- 初期階段的產品
ASG-5ME
ASG-22ME
SGN-19A
財務分析
- 財務實際成果概要
- 營業成本效益分析(2004年∼2010年)
- 營業成本效益分析(2010年∼2016年)
附錄
Description
Introduction
This analysis examines the historical and forecast performance for Seattle Genetics in the prescription pharmaceutical sector. The profile encompasses key product analysis and forecasts, pipeline assessment, and evaluation of company strategy and financial performance over a 6-year period.
Features and benefits
- Gain insight into Seattle Genetics' strategic outlook across the next 6 years
- Analysis of strategically important company products, supported by patient-based forecasting and key opinion leader interviews
Highlights
- Strategic evaluation of Seattle Genetics' outlook for the next six years. Assessment of key strengths, weaknesses, opportunities and threats and appraisal of the company's product portfolio, pipeline and commercial relationships.
Your key questions answered
- After demonstrating impressive response rates in Phase II trials, see how uptake of Adcetris will drive Seattle Genetics' performance
- Assess the potential of Adcetris based on market size, reimbursement issues, and future indications
- Evaluate the company's long-term prospects, based on a strong technology platform and a long pipeline of innovative antibody-drug conjugates
TOC
Executive Summary
- Company introduction
- Recent developments
- Corporate relationships
- Strategic overview
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
ABOUT THIS REPORT
- PharmaVitae Explorer database
- Chapter structure
- Sales and product analysis
- Financial analysis
- Data sourcing
SALES AND PRODUCT ANALYSIS
- Sales overview
- Product analysis
- Adcetris (brentuximab vedotin)
- Hodgkin's lymphoma background
- Anaplastic large cell lymphoma background
- Adcetris clinical trials
- Hodgkin's lymphoma pivotal trial
- Anaplastic large cell lymphoma pivotal trial
- Ongoing and planned clinical trials
- Clinical and commercial attractiveness
- Key forecasting assumptions
- Early-stage products
ASG-5ME
ASG-22ME
SGN-19A
FINANCIAL ANALYSIS
- Financial performance overview
- Operating costs and profit analysis, 2004-10
- Operating costs and profit analysis, 2010-16
APPENDIX
- References
- Exchange rates
|
